EXAI - Exscientia - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

241.1M

Cash

400.2M

Avg Qtr Burn

-43.18M

Short % of Float

2.17%

Insider Ownership

27.88%

Institutional Own.

28.57%

Qtr Updated

06/30/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
EXS21546 (A2A receptor antagonist) Details Cancer, Non-small cell lung carcinoma, Renal cell carcinoma	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GTAEXS617 (CDK7 inhibitor) Details Solid tumor/s, Cancer	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
EXS4318 (PKC-theta Inhibitor) Details Inflammatory disease	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.